Stock Research for ADRD


Featured Broker: Ally Invest

Get the due diligence for another stock.


ADRD Stock Chart & Research Data

The ADRD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ADRD Due diligence Resources & Stock Charts

The ADRD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ADRD Detailed Price Forecast - CNN Money CNN View ADRD Detailed Summary - Google Finance
Yahoo View ADRD Detailed Summary - Yahoo! Finance Zacks View ADRD Stock Research & Analysis -

Stock Analysis

TradeIdeas View ADRD Trends & Analysis - Trade-Ideas Barrons View ADRD Major Holders - Barrons
NASDAQ View ADRD Call Transcripts - NASDAQ Seeking View ADRD Breaking News & Analysis - Seeking Alpha
Spotlight View ADRD Annual Report - OTC Report View ADRD OTC Short Report -
TradeKing View ADRD Fundamentals - TradeKing Charts View ADRD SEC Filings - Bar Chart
WSJ View Historical Prices for ADRD - The WSJ Morningstar View Performance/Total Return for ADRD - Morningstar
MarketWatch View the Analyst Estimates for ADRD - MarketWatch CNBC View the Earnings History for ADRD - CNBC
StockMarketWatch View the ADRD Earnings - StockMarketWatch MacroAxis View ADRD Buy or Sell Recommendations - MacroAxis
Bullish View the ADRD Bullish Patterns - American Bulls Short Pains View ADRD Short Pain Metrics -

Social Media Mentions

StockTwits View ADRD Stock Mentions - StockTwits PennyStocks View ADRD Stock Mentions - PennyStockTweets
Twitter View ADRD Stock Mentions - Twitter Invest Hub View ADRD Investment Forum News - Investor Hub
Yahoo View ADRD Stock Mentions - Yahoo! Message Board Seeking Alpha View ADRD Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ADRD - Insider Cow View Insider Transactions for ADRD - Insider Cow
CNBC View ADRD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ADRD - OTC Markets
Yahoo View Insider Transactions for ADRD - Yahoo! Finance NASDAQ View Institutional Holdings for ADRD - NASDAQ

Stock Charts

FinViz View ADRD Stock Insight & Charts - StockCharts View ADRD Investment Charts -
BarChart View ADRD Stock Overview & Charts - BarChart Trading View View ADRD User Generated Charts - Trading View

Latest Financial News for ADRD

Novartis’s Key Developments in August
Posted on Thursday August 30, 2018

As we’ve already seen, Novartis (NVS) reported a 7% growth YoY (year-over-year) in revenues to ~$13.16 billion during Q2 2018.

Novartis’s Innovative Medicines Business in Q2 2018
Posted on Wednesday August 29, 2018

As we’ve already seen, Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. Innovative Medicines contributed ~67.4% of Novartis’s total revenues in Q2 2018, a 10% growth YoY (year-over-year) to $8.9 billion.

Analysts’ Recommendations for GlaxoSmithKline Stock
Posted on Wednesday August 15, 2018

This year, analysts expect GlaxoSmithKline’s (GSK) revenue to grow 0.4% YoY (year-over-year) to ~30.3 billion British pounds from ~30.2 billion pounds, and its income margin to narrow YoY to 17.9% from 18.1%. They expect it to report EPS of 110.75 pence.

Analyzing GlaxoSmithKline’s Revenue Trends
Posted on Monday August 13, 2018

In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.